Eprim500 mg

Eprim 500 mg is indicated in: Premenstrual syndrome symptoms (PMS) Cyclical mastalgia Lactation

Herbal and Nutraceuticals

Improves EFA composition of plasma, erythrocyte, platelet lipids and α-tocopherol levels in non-diabetic persons and Type 1 diabetic patients; increases total fat and EFA content of mother's milk; affects fatty acid composition of serum lipids and adipose tissue in men with low dihomo-gamma-linolenic acid (DGLA) levels; helps maintain normal cellular structures and is the precursor of DGLA, which is the parent of the 1-series prostanoids and as a precursor of arachidonic acid, the parent of the 2-series prostanoids. In vitro: Cytostatic activity on malignant cell lines; suppresses cancer cell proliferation of human osteogenic sarcoma cells.Eprim 500 mg (EPO) supplies gamma linolenic acid (GLA). The bioactivity of EPO is due primarily to its GLA content. By supplying GLA, it bypasses the rate-limiting step in the metabolism of LA. After ingestion of EPO, GLA is rapidly absorbed and then converts directly to DGLA and other prostaglandin precursors. It also acts on the prostanoid pathway.

One or two capsules two to three times daily or as advised by the physician.

There are no known drug interactions. Steroids and nonsteroidal anti-inflammatory drugs may potentially interfere with essential fatty acid metabolism.

Previously it was not recommended for patients diagnosed with schizophrenia or those already receiving epileptogenic drugs such as phenothiazines. However, a recently published analysis of clinical trials involving polyunsaturated fatty acids in the treatment of schizophrenia did not indicate a clear therapeutic or adverse effect of Eprim 500 mg supplements on schizophrenic patients.

Adverse effects are rare at recommended dosages. Overdose may cause loose stool and abdominal pain.

No known restrictions. Non-teratogenic, based on animal studies. LA, GLA, and DGLA are important components of human breast milk, so it is reasonable to assume that Eprim 500 mg may be taken while nursing. According to World Health Organization (WHO), pregnant or lactating women should get 5% of their total daily caloric intake from EFAs.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.